Biotech Strategy Blog

Commentary on Science, Innovation & New Products with a focus on Oncology, Hematology & Cancer Immunotherapy

Posts tagged ‘Pharma Strategy’

It’s Wednesday at the 2018 JP Morgan Healthcare Conference and the last full day of the meeting. 

San Francisco Cable Car

It’s also our last day for a rolling blog; we hope you’ve enjoyed our coverage and commentary this year.

If you want to catch up on what we’ve written about, do check out our posts form Day 1 (Link) and Day 2 of JPM18 (Link).

We’re also continuing our series of CEO interviews. Check out the latest with Michael Gilman, PhD from Obsidian Therapeutics (Link).

To read our rolling #JPM18 blog, subscribers can log-in or you can purchase access to BSB Premium Content.

This content is restricted to subscribers

It’s Tuesday at the 2018 JP Morgan Healthcare conference in San Francisco…

Rain in San Francisco

Each day of #JPM18 we’re doing a rolling blog post which we’re updating throughout the day with commentary and insights on the company presentations we’re covering.

While we’re not giving a blow-by-blow account, we will be commenting on noteworthy news, and what we learn about pharma/biotech corporate strategy going into 2018.

For those of you who like to catch up with the final summary of each day’s highlights, you can read our post and commentary around Day 1 here (Link).

We’ve also posted a new interview with the Syros CEO, Dr Nancy Simonian, as part of our ASH/JPM18 crossover series.  Syros are presenting on Thursday but had data last month at both SABCS and ASH.

To learn more and get a heads up on our latest insights, subscribers can log-in or you can click to gain access to BSB Premium Content.

This content is restricted to subscribers

Free Email Updates
Subscribe to new post alerts, offers, and additional content!
We respect your privacy and do not sell emails. Unsubscribe at any time.
error: Content is protected !!